The savings from the new list prices for those drugs were expected to generate about $6 billion for taxpayers and $1.5 billion for Medicare enrollees.

who has been looking into the incredible success of the drug on the private market, and also speaks to Sarah Le Brocq, who as well as advising the NHS on the cost-effectiveness of weight loss ...